Estevão-Pereira H, Lobo J, Salta S, et al. - Because breast cancer (BrC) continues to be the leading cause for cancer-related mortality in women—primarily due to repeated and/or metastatic events—experts evaluated the biomarker performance of microRNAs previously reported as correlated with prognosis for prognosticating BrC progression in liquid biopsies. Selected microRNAs were evaluated utilizing a quantitative reverse transcription-polymerase chain reaction in a testing cohort of formalin-fixed paraffin-embedded primary (n = 16) and metastatic BrC tissues (n = 22). MiR-30b-5p was variably manifested in primary tumors and paired metastatic lesions, with bone metastases exhibiting notably higher miR-30b-5p expression levels, paralleling the analogous primary tumors. The researchers found that MiR-30b-5p might identify BrC individuals at greater risk of disease progression, therefore, providing a beneficial clinical tool for people’ monitoring, entailing previously and more efficient treatment. However, validation in larger multicentric cohorts is necessary to confirm these results.